CoChat
Sign Up
Cited by 11Colorectal Cancer Treatments and StudiesAngiogenesis and VEGF in CancerColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Update on Anti-angiogenesis Therapy in Colorectal Cancer

Open access
Ciombor, Kristen K., Goldberg, Richard M.·2015·Current Colorectal Cancer Reports
DOI 10.1007/s11888-015-0292-3PMC PMC4991548
Open this paper in CoChat — free account

Abstract

Angiogenesis is a complex biologic process critical to growth and proliferation of colorectal cancer. The safety and efficacy of various anti-angiogenic agents have been investigated in many treatment settings. Bevacizumab, an anti-vascular endothelial growth factor agent, has efficacy in both the first-line setting and beyond progression in metastatic colorectal cancer. The decoy vascular endothelial growth factor receptor aflibercept has been approved in combination with 5-fluorouracil, leucovorin and irinotecan-based chemotherapy in metastatic colorectal cancer patients whose disease has progressed on a prior oxaliplatin-based chemotherapy regimen. The multikinase inhibitor regorafenib is modestly effective in the refractory colorectal cancer setting but confers significant toxicity. Ramucirumab, an anti-vascular endothelial growth factor receptor 2 molecule, has efficacy in combination with 5-fluorouracil, leucovorin and irinotecan after disease progression on a first-line bevacizumab-, oxaliplatin- and fluoropyrimidine-containing regimen. Questions regarding optimal treatment setting, predictive biomarkers of response, and cost effectiveness of these anti-angiogenic agents and others are as yet unanswered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11888-015-0292-3

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Few clinical trials suggested an improved response rate with bevacizumab plus EGFR inhibitors, while others showed increased toxicity without significant survival benefit.

    “However, few clinical trials suggested an improved response rate, while others showed increased toxicity without significant survival benefit.”

    From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [81]

    The Bevacizumab section reports outcomes for bevacizumab with chemotherapy, including toxicity and survival, but does not address bevacizumab combined with EGFR inhibitors. Searches for EGFR inhibitors, cetuximab, and panitumumab did not locate a passage comparing the claimed response rates, toxicity, or survival for that combination. No page numbers were provided in our copy. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 40

  1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6. · DOI · Paper page
  2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–76. · DOI · Paper page
  3. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–9.
  4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. · DOI · Paper page
  5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern cooperative oncology group study E3200. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(12):1539–44. · DOI · Paper page
  6. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26(12):2013–9. · DOI · Paper page
  7. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26(33):5326–34. · DOI
  8. Grothey A, Flick ED, Cohn AL, et al. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf. 2014;23(7):726–34. · DOI
  9. Allegra CJ, Yothers G, O'Connell MJ, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(3):359–64. · DOI
  10. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(20):3385–90. · DOI
  11. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225–33. · DOI · Paper page
  12. Lambrechts D, Lenz HJ, de Haas S, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(9):1219–30. · DOI
  13. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393–8. · DOI · Paper page
  14. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(2):207–14. · DOI
  15. Van Cutsem E, Khayat D, Verslype C, et al. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer. 2013;49(1):17–24. · DOI
  16. Khayat D, Tejpar S, Spano JP, et al. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. Eur J Cancer. 2013;49(4):790–7. · DOI
  17. Tang PA, Cohen SJ, Kollmannsberger C, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(21):6023–31. · DOI
  18. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(28):3499–506. This phase III trial demonstrated the superiority of aflibercept versus placebo in combination with FOLFIRI for second-line mCRC therapy. · DOI · Paper page
  19. Tabernero J, Van Cutsem E, Lakomy R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50(2):320–31. · DOI
  20. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer J Int du Cancer. 2011;129(1):245–55. · DOI · Paper page
  21. Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(9):2658–67. · DOI
  22. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73–4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106(11):1722–7. · DOI
  23. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. This phase III trial showed the survival benefit of regorafenib in comparison to placebo in the refractory mCRC setting. · DOI · Paper page
  24. Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–29. This phase III trial in an Asian patient population demonstrated increased efficacy of regorafenib in refractory mCRC patients when compared with the CORRECT trial. · DOI · Paper page
  25. Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Annals Oncol: Off J Eur Soc Med Oncol / ESMO. 2013;24(6):1560–7. · DOI
  26. Argiles G, Saunders MP, Rivera F, et al. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. Eur J Cancer. 2015;51(8):942–9. · DOI
  27. Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015. · DOI
  28. Lu D, Jimenez X, Zhang H, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer J Int du Cancer. 2002;97(3):393–9. · DOI
  29. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(5):780–7. · DOI
  30. Chiorean EG, Hurwitz HI, Cohen RB, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Annals Oncol: Off J Eur Soc Med Oncol / ESMO. 2015;26(6):1230–7. · DOI
  31. Yoshino T, Yamazaki K, Gotoh M, et al. Safety and pharmacokinetics of second-line Ramucirumab plus FOLFIRI in Japanese patients with metastatic colorectal carcinoma. Anticancer Res. 2015;35(7):4003–7.
  32. Wang DBF, Lee JJ, Denlinger CS, Shepard DR, Chaudhary A, Lin Y, et al. Phase II study evaluating the effect of concomitant ramucirumab on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil in patients with advanced malignant solid tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33 suppl 3:691. · DOI
  33. Garcia-Carbonero R, Rivera F, Maurel J, et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist. 2014;19(4):350–1. · DOI
  34. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–82. · DOI · Paper page
  35. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16(1):311–9. This phase I study demonstrated the safety and potential efficacy of nintedanib in patients with advanced solid tumors. · DOI
  36. Mross K, Buchert M, Frost A, et al. Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer. 2014;14:510. · DOI
  37. Lange A, Prenzler A, Frank M, et al. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer. 2014;50(1):40–9. This systematic review evaluated published analyses of cost effectiveness studies involving monoclonal antibody use for mCRC. · DOI
  38. Shankaran V, Mummy D, Koepl L, et al. Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. Oncologist. 2014;19(8):892–9. · DOI
  39. Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33(10):1112–8. · DOI
  40. Wade R, Duarte A, Simmonds M, et al. The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: a critique of the evidence. Pharmaco Econ. 2015;33(5):457–66. · DOI

Cited by

Sorted by citations

Metadata

Authors
Ciombor, K. K., & Goldberg, R. M.
Affiliations
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Corresponding author
Goldberg, Richard M.
ORCID
Venue
Current Colorectal Cancer Reports
Publisher
Springer Science and Business Media LLC
Published
2015-09-04
Volume
11
Issue
6
Pages
378-387
ISSN
  • 1556-3790 (ISSN-L)
  • 1556-3804
DOI
10.1007/s11888-015-0292-3
PMC
PMC4991548
OpenAlex
W2145988365
Cited by
11
References
2
Citations by year
2026: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 1
FWCI
0.44
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Colorectal Cancer Reports (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA016086)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
anti-angiogenic therapy, colorectal cancer, metastatic colorectal cancer, bevacizumab, aflibercept, regorafenib, ramucirumab, vascular endothelial growth factor, VEGFR2, multikinase inhibitor, 5-fluorouracil, irinotecan, oxaliplatin, predictive biomarkers, cost-effectiveness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review